NCT02146469

Brief Summary

The objective of the study is as follows:

  1. 1.To know the antibody level during different interval after received 1 dose varicella vaccine.
  2. 2.To know safety and effectiveness of received 2 doses varicella vaccine with different interval.
  3. 3.To know safety and effectiveness of received varicella vaccine and MMR at the same time.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Dec 2012

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

May 21, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 23, 2014

Completed
9 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

May 23, 2014

Status Verified

May 1, 2014

Enrollment Period

1.5 years

First QC Date

May 21, 2014

Last Update Submit

May 21, 2014

Conditions

Keywords

varicella vaccination

Outcome Measures

Primary Outcomes (1)

  • Seroconversion rate and GMCs after varicella vaccination

    35-42 days after each dose vaccination

Secondary Outcomes (1)

  • The incidence of Adverse Events Following Immunization

    30 days after each dose vaccination

Study Arms (6)

None varicella vaccine history

EXPERIMENTAL

2 doses with an 3 months interval

Biological: 2 doses with an 3 months interval

1 year after first dose

EXPERIMENTAL

A second dose with an 1 year interval

Biological: A second dose with an 1 year interval

3 years after first dose

EXPERIMENTAL

A second dose with an 3 year interval

Biological: A second dose with an 3 year interval

5 years after first dose

EXPERIMENTAL

A second dose with an 5 year interval

Biological: A second dose with an 5 year interval

Testing group for conbined immunization

EXPERIMENTAL

1 dose Varicella vaccine and 1 dose MMR given at the same time

Biological: 1 dose Varicella vaccine and 1 dose MMR given at the same time

Control group for conbined immunization

PLACEBO COMPARATOR

1 dose MMR

Biological: 1 dose MMR

Interventions

varicella vaccination

None varicella vaccine history

varicella vaccine

1 year after first dose

varicella vaccine

3 years after first dose

varicella vaccine

5 years after first dose

varicella vaccine and MMR

Testing group for conbined immunization
1 dose MMRBIOLOGICAL

MMR

Control group for conbined immunization

Eligibility Criteria

Age1 Year - 7 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Aged 1 to 7
  • Without a previous history of varicella
  • With an axillary temperature ≤37.5℃ at the time of vaccination
  • Appropriate varicella vaccination history
  • With guardian signing the informed consent and available for clinical observation

You may not qualify if:

  • Hypersensitive to any active substance of the vaccine including excipients and antibiotics
  • With acute illness, severe or acute attack of chronic illness or fever
  • With immunodeficiency or weakened immune system or being treated with immunosuppressant drugs
  • Suffering a brain disease, uncontrolled epilepsy or progressive nerve system disease
  • With a family or personal history of seizure, chronic illness, epilepsy or allergy
  • With unknown immunization history or unable to follow the immunization schedule of EPI
  • Received any vaccine within 4 weeks or willing to receive any vaccine in 1 month
  • With hemorrhagic tendency or prolonged period of bleeding
  • Received whole blood, plasma or immunoglobulin within 5 months
  • Received systemic antibiotics or antiviral treatment for acute illness within 7 days
  • With an axillary temperature ≥38℃ within 3 days
  • Participating in another clinical trial
  • Any situation that might influence the consequence of the clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai municipal center for disease control and prevention

Shanghai, Shanghai Municipality, 021, China

Location

MeSH Terms

Conditions

Chickenpox

Interventions

Chickenpox Vaccine

Condition Hierarchy (Ancestors)

Varicella Zoster Virus InfectionHerpesviridae InfectionsDNA Virus InfectionsVirus DiseasesInfections

Intervention Hierarchy (Ancestors)

Herpesvirus VaccinesViral VaccinesVaccinesBiological ProductsComplex Mixtures

Study Officials

  • Xiaodong Sun

    Shanghai Municipal Center for Disease Control and Prevention

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 21, 2014

First Posted

May 23, 2014

Study Start

December 1, 2012

Primary Completion

June 1, 2014

Study Completion

December 1, 2014

Last Updated

May 23, 2014

Record last verified: 2014-05

Locations